These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30849460)

  • 1. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product.
    Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P
    J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multicompany Assessment of Submicron Particle Levels by NTA and RMM in a Wide Range of Late-Phase Clinical and Commercial Biotechnology-Derived Protein Products.
    Hubert M; Yang DT; Kwok SC; Rios A; Das TK; Patel A; Wuchner K; Antochshuk V; Junge F; Bou-Assaf GM; Cao S; Saggu M; Montrond L; Afonina N; Kolhe P; Loladze V; Narhi L
    J Pharm Sci; 2020 Jan; 109(1):830-844. PubMed ID: 31647951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
    Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
    Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection.
    Allen LV
    Int J Pharm Compd; 2022; 26(3):219-228. PubMed ID: 35657746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sterile Basics: Intravenous Admixture Preparation Considerations, Part 4: Particulates.
    Allen LV
    Int J Pharm Compd; 2020; 24(3):215-220. PubMed ID: 32401741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of subvisible particles in therapeutic proteins.
    Singh SK; Toler MR
    Methods Mol Biol; 2012; 899():379-401. PubMed ID: 22735966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subvisible Particulate Contamination in Cell Therapy Products-Can We Distinguish?
    Vollrath I; Mathaes R; Sediq AS; Jere D; Jörg S; Huwyler J; Mahler HC
    J Pharm Sci; 2020 Jan; 109(1):216-219. PubMed ID: 31521641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Particle Techniques for the Characterization of Subvisible Particles From Elastomeric Closure Components.
    Rech J; Fradkin A; Krueger A; Kraft C; Paskiet D
    J Pharm Sci; 2020 May; 109(5):1725-1735. PubMed ID: 32017902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
    Gervais D; Corn T; Downer A; Smith S; Jennings A
    AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Clinical Safety and Analytical Impact of Subvisible Silicone Oil Particles in Biopharmaceutical Products.
    Saggu M; Bou-Assaf GM; Bucher R; Budyak IL; Buecheler J; Cao S; Groenning M; Khan E; Kwok SC; Minocha S; Pisupati K; Radhakrishnan V; Videbæk N; Yang DT; Zhang B; Narhi LO
    J Pharm Sci; 2024 May; 113(5):1401-1414. PubMed ID: 38220088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues and challenges of subvisible and submicron particulate analysis in protein solutions.
    Scherer TM; Leung S; Owyang L; Shire SJ
    AAPS J; 2012 Jun; 14(2):236-43. PubMed ID: 22391789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basics of Sterile Compounding: Particulate Matter.
    Akers MJ
    Int J Pharm Compd; 2017; 21(5):395-404. PubMed ID: 29216617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closing the Gap: Counting and Sizing of Particles Across Submicron Range by Flow Cytometry in Therapeutic Protein Products.
    Zhang L; Shi S; Antochshuk V
    J Pharm Sci; 2017 Nov; 106(11):3215-3221. PubMed ID: 28625725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
    Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
    J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taking Subvisible Particle Quantitation to the Limit: Uncertainties and Statistical Challenges With Ophthalmic Products for Intravitreal Injection.
    Gühlke M; Hecht J; Böhrer A; Hawe A; Nikels F; Garidel P; Menzen T
    J Pharm Sci; 2020 Jan; 109(1):505-514. PubMed ID: 31682829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of protein particles in parenteral solutions using micro-flow imaging.
    Huang CT; Sharma D; Oma P; Krishnamurthy R
    J Pharm Sci; 2009 Sep; 98(9):3058-71. PubMed ID: 18937372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential clinical relevance of visible particles in parenteral drugs.
    Doessegger L; Mahler HC; Szczesny P; Rockstroh H; Kallmeyer G; Langenkamp A; Herrmann J; Famulare J
    J Pharm Sci; 2012 Aug; 101(8):2635-44. PubMed ID: 22628244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.